REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
07/03/2026
Voltar para busca
Dado oficial do USPTO
VIRTUS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
44
Atualização mais recente
08/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 35, 42
Data de depósito
06/04/2015
Data de registro
03/01/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
08/09/2023
Última transação
08/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
702
Cadastro oficial
Principal Register
Primeiro uso
01/10/2011
Primeiro uso no comércio
01/10/2011
Código do desenho
4
Tipo de titular
16
Localização do titular
Newtown, PA, US
Examinador
WHEATLEY, TRAVIS DWIGHT
Unidade examinadora
M80
Localização atual
TMO LAW OFFICE 117
Titulares e representantes
Titulares
Virtus Pharmaceuticals, LLC
Virtus Pharmaceuticals, LLC
Representantes
Laurence Tauber Cohen Tauber Speivack & Wgner P.C.
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticalsprescription and over-the-counter drugs for the treatment of illnessdisease or deficienciesbacterial infectionstreatment symptoms of seasonalperennial and chronic allergies and the treatment of skin hives and itching associated with skin reactionsType 2 diabetes mellitusTreatment and prevention of osteoporosis in postmenopausal womentreatment to increase bone mass in men with osteoporosistreatment of glucocorticoid induced osteoporosisTreatment of Paget's Disease of boneTreatment for the relief of discomfort associated with acute or painful musculoskeletal conditionsTreatment and management of moderate to moderately-severe pain in adultsTreatment of hypertensionTreatment of diabetic nephropathyTreatment of dermatitis herpetiformis and leprosyTreatment of chronic inflammatory skin disease marked by blistersTreatment of acid indigestionTreatment of upset stomachManagement and support for patients requiring increased folate levelsSupplementation in support of bone healthSupplementation in support of prenatal healthincludingwithout limitationincreased folic acidManagement and support of absorption of calcium and/or functioning of calcium in the bodyTreatment of Vitamin D deficiencySupplementation in support of postnatal healthTreatment and prevention of lack of vitaminsminerals and/or fatty acids during pregnancyTreatment and temporary relief of coughnasal congestionloosening of phlegm and thin bronchial secretionsTreatment and prevention of prenatal and postnatal folate deficiencyTreatment of elevated or high levels of uric acid and prevention and treatment of metabolic problems caused by kidney diseaseprevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tabletshormone replacement therapyPostnatal supplementation and improvement of nutritional states of women prior to conceptionprevention of acidosisstomach or bowel problemspeptic ulcers and irritable bowel syndromeTreatment for excessive saliva productionirritable colon and bladder dysfunctionTreatment of symptoms associated with disorders of gastrointestinal tractbladder spasmspeptic ulcer diseasediverticulitisirritable bowel syndromecystitis and pancreatitisPrevention and treatment of low blood levels of potassiumPrevention of Fetal Neural Tube Defects when pregnantTreatment of inadequate folic acidfolate deficiencyanemia from inadequate folic acidTreatment of Hyperhomocysteinemia
Classe 35
Distributorship services in the field of prescription and over-the-counter drugs; marketing of prescription and over-the-counter drugs
Classe 42
Development of pharmaceutical products
Publicações
Histórico de despachos e eventos da marca no USPTO.
44 publicações encontradas
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
08/09/2023
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
08/09/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/09/2023
E815
TEAS SECTION 8 & 15 RECEIVED
10/03/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
03/01/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/01/2017
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/01/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
03/01/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/10/2016
PUBO
PUBLISHED FOR OPPOSITION
18/10/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/09/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
14/09/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/09/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
31/08/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
31/08/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
31/08/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
31/08/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/08/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/08/2016
ALIE
ASSIGNED TO LIE
13/08/2016
NREV
NOTICE OF REVIVAL - E-MAILED
05/08/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/08/2016
PETG
PETITION TO REVIVE-GRANTED
04/08/2016
PROA
TEAS PETITION TO REVIVE RECEIVED
04/08/2016
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
18/07/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
18/07/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/02/2016
GNRT
NON-FINAL ACTION E-MAILED
03/02/2016
CNRT
NON-FINAL ACTION WRITTEN
03/02/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/01/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/01/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/01/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/07/2015
GNRT
NON-FINAL ACTION E-MAILED
21/07/2015
CNRT
NON-FINAL ACTION WRITTEN
21/07/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
20/07/2015
GNRT
NON-FINAL ACTION E-MAILED
20/07/2015
CNRT
NON-FINAL ACTION WRITTEN
20/07/2015
DOCK
ASSIGNED TO EXAMINER
14/07/2015
TAEA
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
30/04/2015
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
30/04/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/04/2015
NWAP
NEW APPLICATION ENTERED
09/04/2015
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VIRTUS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.